Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV crossover study of Pulmozyme delivered via eRapid nebulizer in cystic fibrosis
2015-003537-99Phase 4
- Sponsor
- Roche
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Roche. Primary endpoint: Stability of lung function.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-003537-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003537-99.